FY2026 EPS Estimates for NeuroPace Lifted by HC Wainwright

NeuroPace, Inc. (NASDAQ:NPCE) – HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for NeuroPace in a research report issued on Friday, May 15th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($0.69) for the year, up from their prior forecast of ($0.72). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for NeuroPace’s current full-year earnings is ($0.44) per share.

A number of other equities analysts have also weighed in on the company. Wells Fargo & Company upgraded NeuroPace to a “strong-buy” rating in a research note on Wednesday, March 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NeuroPace in a research note on Friday, March 27th. Wall Street Zen lowered NeuroPace from a “buy” rating to a “hold” rating in a research note on Sunday, March 15th. Finally, Cantor Fitzgerald upgraded NeuroPace to a “strong-buy” rating in a research note on Wednesday, March 4th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $18.83.

NeuroPace Price Performance

Shares of NASDAQ NPCE opened at $16.28 on Friday. The firm has a market cap of $554.99 million, a P/E ratio of -25.05 and a beta of 1.92. The company has a current ratio of 5.38, a quick ratio of 4.35 and a debt-to-equity ratio of 4.08. NeuroPace has a 1-year low of $7.56 and a 1-year high of $19.60. The business’s 50 day moving average is $15.28 and its 200-day moving average is $15.27.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.06. The company had revenue of $22.00 million during the quarter, compared to analysts’ expectations of $21.65 million. NeuroPace had a negative return on equity of 108.20% and a negative net margin of 21.67%.

Hedge Funds Weigh In On NeuroPace

A number of hedge funds have recently added to or reduced their stakes in NPCE. Geode Capital Management LLC increased its stake in NeuroPace by 44.6% during the 2nd quarter. Geode Capital Management LLC now owns 485,162 shares of the company’s stock worth $5,406,000 after acquiring an additional 149,595 shares during the period. Legal & General Group Plc increased its stake in NeuroPace by 86.0% during the 2nd quarter. Legal & General Group Plc now owns 2,679 shares of the company’s stock worth $30,000 after acquiring an additional 1,239 shares during the period. Rhumbline Advisers increased its stake in NeuroPace by 114.5% during the 2nd quarter. Rhumbline Advisers now owns 36,956 shares of the company’s stock worth $412,000 after acquiring an additional 19,729 shares during the period. Russell Investments Group Ltd. increased its stake in NeuroPace by 59.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 71,463 shares of the company’s stock worth $796,000 after acquiring an additional 26,547 shares during the period. Finally, Quantbot Technologies LP bought a new position in NeuroPace during the 2nd quarter worth $35,000. Institutional investors own 78.83% of the company’s stock.

About NeuroPace

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.